Organoid-based evaluation of SA55 and Pemivibart against evolving SARS-CoV-2 variants
Zhixin Wan(University of Hong Kong), Jie Zhou(Zimmer Biomet (Netherlands)), Man Chun Chiu(Unknown), Fanchong Jian(Pioneer (United States)), Qiaoshuai Lan(Chinese University of Hong Kong), Xinjie Meng, Y. Liu(Chinese University of Hong Kong), Shuxin Zhang(Beijing Jiaotong University), Cun Li(Xinjiang Medical University), Zijun Zhao(University of Hong Kong), Xiang Gao(Czech Academy of Sciences, Institute of Biotechnology), Yunlong Cao(Peking University), Xiaoxin Zhu(Chinese University of Hong Kong), Wei Xue(University of Hong Kong), Jingjing Huang(Hong Kong Science and Technology Parks Corporation), Yifei Yu(Hong Kong Science and Technology Parks Corporation), Ying Zhou(Hong Kong Science and Technology Parks Corporation), Yidong Yang(University of Hong Kong), Jiali Wu(University of Hong Kong), Hin Chu(Hong Kong Science and Technology Parks Corporation), Lin Huang(Sichuan Agricultural University)
Cited by 0
Related Papers
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
|Cell Research|2020|1.4k
Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
|Cellular and Molecular Immunology|2020|759
Infection of bat and human intestinal organoids by SARS-CoV-2
|Nature Medicine|2020|552
Middle East Respiratory Syndrome Coronavirus Efficiently Infects Human Primary T Lymphocytes and Activates the Extrinsic and Intrinsic Apoptosis Pathways
|The Journal of Infectious Diseases|2015|472